Celgene announces shock departure of COO

pharmafile | February 27, 2017 | News story | Medical Communications, Sales and Marketing Celgene 

Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. She will continue to fulfil her role until 1 April and continue to serve as strategic advisor beyond this period onto 1 June.

The news has come something of a surprise, with much speculation taking place as to the reasons behind it. Some have linked it to the appointment of Mark Alles as Chief Executive Officer, with Fouse believed to have thrown her hat into the ring for this role but was eventually passed over in favour of Alles.

There has been some speculation that Fouse may have been offered a CEO role or, alternatively, wants to take a short-term break away from the industry. At only 56 years of age, the likelihood of an actual ‘retirement’, as it has been referred to, seems unlikely.

Fouse’s role will be filled by Scott Smith, who takes the role after having launched Celgene’s Inflammation & Immunocology franchise and will take up the post immediately after Fouse vacates the role on 1 April. His position, in turn, will be filled by Terrie Curran – who will take the position of President, Global I&I Franchise.

“I would like to thank Jackie for her incredible commitment and dedication to Celgene and the patients we seek to serve worldwide,” said Mark Alles, Chief Executive Officer of Celgene. “On behalf of all Celgene employees, I wish Jackie the best in her retirement.”

How long that retirement will be, remains to be seen. There will be many within the industry keeping an eye on her next move.

Ben Hargreaves

Related Content


NICE recommends Celgene’s REVLIMID for multiple myeloma

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …


NICE recommends Celgene’s Revlimid combo for follicular lymphoma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …

Latest content